2-Week Study In People With Nonalcoholic Fatty Liver Disease

• Status: Completed
• Trial end date: 2019-04-04
• Target enrollment: 0
• Participant gender: All

Summary

2-week study in people with nonalcoholic fatty liver disease. Study drug at 1 of 2 doses, or placebo, will be given for 14 days. Blood samples, heart monitoring, vital signs, and imaging procedures will be performed.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• controlled attenuation parameter greater than or equal to 260 dB/m via FibroScan

• liver fat greater than or equal to 6% via MRI

Exclusion Criteria:

• Chronic liver disease

• Type 2 diabetes requiring drug treatment

• Unable to undergo MRI

• History of heart attack or stroke